Quick Facts

• Support for damaged liver cells: Used as an adjunctive agent to assist liver function in various conditions.
• Support for tissue repair: Indicated to help support the body's natural processes of regeneration and healing.
• Surgical recovery support: Utilized in a complementary capacity to assist recovery following certain surgical procedures.

---

Main Uses and Therapeutic Areas

Ксимедон is a pharmaceutical preparation generally utilized in a supportive role across several therapeutic domains, primarily within specific regulatory jurisdictions. The substance, chemically known as 1-(2-hydroxyethyl)-4,6-dimethyl-2(1H)-pyrimidinone, is often associated with properties that support the body's natural ability to renew and maintain tissues.

In clinical practice, it is sometimes included as an adjuvant agent to complement the primary treatment regimen. Specific applications where it may be employed include situations requiring support for the body's repair processes, such as following surgical interventions to assist with tissue regeneration and healing of the surgical site. Furthermore, the substance has been investigated for its capacity to offer supportive care for the liver, particularly in contexts involving exposure to certain toxic elements or stress that may affect the organ's function.

The therapeutic intent of this preparation is to act as a supportive supplement to other treatments in an effort to contribute to positive outcomes related to the maintenance of tissue integrity and organ function.

Regulatory References

1. NIH MedlinePlus guidance

Who Can and Cannot Use Ксимедон?

The population eligibility for Ксимедон (Hydroxiethyldimethyldihydropyrimidine) is defined by its official regulatory label, which establishes strict non-eligibility rules.

---

Eligibility Scope	Regulatory Classification
Populations Contraindicated	Absolute prohibition for individuals diagnosed with Acute Leukemia, Chronic Leukemia, or Erythremia (Polycythemia vera). The medicine is also prohibited for patients with known Hypersensitivity to the active substance or excipients.
Allowed Populations	Individuals undergoing treatment for labeled conditions, such as deep and superficial burns, infected wounds, and trophic ulcers, are typically eligible.

---

Eligibility-Related Restrictions

Age-Related Eligibility: The official regulatory documentation does not establish formal rules for use in pediatric populations, meaning its safety and efficacy are not confirmed for children and adolescents. Standard use is confined to the adult population.

Special Physiological States and Organ Function: The label provides no specific guidance or clearance status for use during pregnancy or lactation. Furthermore, no explicit restrictions or requirements for special consideration regarding renal impairment or hepatic impairment are documented in the official contraindication sections.

Connection to the overall eligibility profile: The regulatory documents primarily define who is formally excluded from treatment by listing absolute, comorbidity-linked prohibitions. Use in populations where guidance is absent—including pediatric and pregnant individuals—is considered not established by the official label.

Interactions with other medicines and products

Official regulatory information for Ксимедон (Hydroxiethyldimethyldihydropyrimidine) identifies a focused set of drug interactions based on pharmacodynamic effects, as documented by national regulatory authorities where the product is approved. The interaction profile is primarily characterized by the potential for synergistic action when co-administered with specific drug classes.

---

Documented Interaction Patterns

The most commonly documented interaction involves pharmacodynamic potentiation—the potential for the combined effects of two medicines to be greater than the sum of their individual effects.

• Antioxidant Agents: Co-administration with other medicines possessing antioxidant properties may lead to a potentiation of effects.
• Cardiovascular Agents: Official information notes an increase in the efficacy of certain medications, including antiarrhythmic agents and anti-anginal agents.
• Antihypoxant Agents: Concomitant use with antihypoxant agents (used to manage oxygen deficiency) may also result in a potentiation of effects.

---

Regulatory Constraints

The official regulatory documents do not formally list the following types of interactions or constraints:

Interaction Type	Regulatory Status
Contraindicated Combinations	None formally documented due to interaction risk.
Metabolic (CYP/Transporter) Effects	None explicitly detailed in interaction sections.
Timing-Separation Rules	No mandatory administration spacing rules are documented.
Food/Alcohol Interactions	None are explicitly documented in the regulatory interaction section.

This interaction structure is defined by its focus on potential additive or synergistic effects, rather than pharmacokinetic alterations or absolute prohibitions.

Ксимедон (Xymedon) is a pyrimidine derivative that primarily exerts its effects through modulation of cellular biosynthetic processes and cholesterol metabolism in specific tissues. The compound is selectively accumulated in the liver and blood vascular cells.

At the intracellular level, Xymedon interacts with the mechanisms governing nucleic acid synthesis, acting as a stimulator to increase the de novo synthesis of DNA and RNA in proliferative cells, such as thymocytes and lymphocytes. This action promotes the upregulation of key cellular machinery for growth and repair.

Simultaneously, the drug modulates lipid homeostasis by promoting the reduction of plasma cholesterol levels and decreasing the rate of cholesterol esterification within vascular cells. The downstream cascade of these actions involves alterations in the lipid profile, which results in system-level physiological modulation of lipid transport and deposition in the vascular system. Additionally, the drug exerts a neuro-protective effect on sensory neurons by inhibiting post-traumatic neuronal cell death.

The administration of Ксимедон (Hydroxiethyldimethyldihydropyrimidine) is defined by instructions that specify the route, dosing schedule, and duration of use, based on prescribing information in the relevant jurisdiction.

---

Administration Scope

The preparation is indicated for Oral use (as 250 mg tablets) and Topical use (as a gel or external solution). For systemic therapy, the standard oral schedule involves an individual dose of 0.5 g per administration, which is equivalent to two tablets. The typical total Daily Dose ranges between 1.5 g and 2.0 g. This daily quantity is divided and taken 3 to 4 times per day.

---

Procedural Conditions

An instruction for oral administration is the requirement to take the tablets before meals, establishing the intake condition. Treatment is organized into defined courses generally lasting 1 to 5 weeks. For certain chronic conditions, guidelines permit repeat courses after adhering to a mandatory 6-month interval break. The medicine is often used in a supportive capacity as part of a complex therapeutic regimen. Prescribing information does not generally detail specific high-level dose adjustments for populations such as older adults or those with renal impairment in its core instructions.

Research evidence / Overview of studies for Ксимедон

The research evidence for Ксимедон (Hydroxiethyldimethyldihydropyrimidine) is evaluated strictly by the findings documented in international, authoritative, peer-reviewed sources. A search of major repositories like PubMed and Cochrane indicates that high-quality evidence, such as large Randomized Controlled Trials (RCTs) or comprehensive systematic reviews, is not widely documented in these international listings. The summaries below focus on the known structure of the evidence base and the areas of greatest uncertainty.

---

Research Exploration for Key Indications

Across the three intended uses—Supporting Tissue Repair and Regeneration, Supporting Damaged Liver Cells, and Surgical Recovery Support—the specific study designs, patient populations, and outcomes measured are undocumented in the required peer-reviewed scientific record. For instance, research that has explored the compound for conditions associated with systemic or functional imbalance related to liver cells is not characterized in international literature. Similarly, the existence of high-quality comparative studies for tissue repair or surgical recovery is not confirmed in the international research record. The evidence base for these indications does not contribute to understanding symptom patterns in major global scientific repositories.

---

Research Gaps and Uncertainty

Long-term effects of Ксимедон are not fully established because follow-up durations are not well documented in the accessible evidence. Furthermore, data for special populations, such as children, older adults, or individuals with comorbid conditions, remain insufficient. The certainty regarding the overall evidence base remains low due to the absence of independent, large-scale randomized controlled trials and systematic reviews in globally recognized databases. The evidence quality varies across any potentially existing studies, and characterizing the evidence structure requires further investigation to establish consistency.

Key Studies & References

1. Search of Randomized Controlled Trials and Systematic Reviews (PubMed Database)
2. WHO International Clinical Trials Registry Platform (ICTRP) Search

Common questions about Ксимедон (FAQ)

Q: Does the use of Ксимедон require me to avoid specific foods or beverages?

Official regulatory documents for Ксимедон do not explicitly list specific foods or beverages that must be avoided. However, the official instructions for the oral tablets specify that they should be taken before meals.

It is important to follow the administration conditions provided with the medicine.

Q: Is it safe to consume alcohol in moderation while using Ксимедон?

The official regulatory interaction sections do not explicitly document any interactions between Ксимедон and alcohol.

Concerns regarding alcohol use while taking this medicine may be discussed with a healthcare provider, as the official label does not provide specific guidance.

Q: Is Ксимедон appropriate for use by older adults?

Official documents indicate that specific high-level dose adjustments for older adults are not detailed in the core prescribing instructions.

Additionally, research data examining the safety and efficacy of Ксимедон specifically in the older adult population is stated to be insufficient to draw firm conclusions about its overall appropriateness.

Q: What are the general differences between the tablet and capsule forms of Ксимедон?

The active ingredient in Ксимедон is formulated into several different preparation forms. The tablets are intended for systemic use (taken internally), while the gel or solution preparations are for topical use (applied externally).

Official documents do not list the availability of capsule forms for this medicine.

Q: Are there any known common or mild side effects, gastrointestinal issues, tiredness, dizziness, or signs of serious adverse reactions associated with Ксимедон?

The verifiable public regulatory documentation from major global health agencies currently does not contain a detailed, classified risk structure for side effects.

This means that official data regarding the frequency of common, mild, or serious adverse reactions associated with Ксимедон is unavailable to be presented here.

Storage and Disposal Requirements for Ксимедон

The official storage conditions for Ксимедон (Hydroxiethyldimethyldihydropyrimidine) are mandated by regulatory agencies to maintain its stability and quality.

---

Storage Conditions

• Temperature: The medicine must be stored at a temperature not exceeding 25 C (77 F). The product must be protected from freezing and excessive heat.
• Environment: Store in its original container, which must be kept tightly closed where applicable, and be protected from light and moisture.
• Child Safety: Ксимедон must always be stored out of the sight and reach of children.

---

Disposal Instructions

Unused or expired product must be disposed of strictly in accordance with local regulatory requirements for pharmaceutical waste. Do not dispose of Ксимедон in household trash or pour it down a sink or toilet, as this may contaminate the environment.